Table 3.
Dose reductions and transfusions by dose group
| 120 3/4 | 160 3/4 | 160 3/4, 2/1w | All patients | |
|---|---|---|---|---|
| (n = 25) | (n = 67) | (n = 27)a | (N = 119) | |
| Duration of treatment, weeks | ||||
| Mean (SD) | 24.2 (26.7) | 15.3 (13.5) | 27.3 (34.3) | 19.9 (23.1) |
| Median | 11.4 | 11.4 | 11.1 | 11.4 |
| Range | 2.4–94.3 | 0.4–64.6 | 0.4–117.1 | 0.4–117.1 |
| Dose reduction due to AE, no. (%) | 7 (28.0) | 25 (37.3) | 4 (14.8) | 36 (30.3) |
| Subjects with RBC transfusion (for grade 3 anemia), no. (%) | 5 (20.0) | 19 (28.4) | 2 (7.4) | 26 (21.8) |
a
One patient from the 160 3/4, 2/1w group had dose reduced to 120 3/4, 2/1w due to a medical history of grade 2 anemia (not a TRAE). 2/1w = 2 weeks on, 1 week off; 120 3/4 = 120 mg QD 3 days on, 4 days off; 160 3/4 = 160 mg QD 3 days on, 4 days off; AE = adverse event; QD = once daily; RBC = red blood cell; SD = standard deviation; TRAE, treatment-related AE.